One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The new mirror summary retains the MDRD table and the distinct trial CrCl exclusion; current official confirmation was not obtained.
What to reconcile: Do not compound separate reduction rules or treat a trial-entry exclusion as an approved renal cutoff.
Open this note and its source references| Label eGFR | Starting oral dose |
|---|---|
| 60-89 mL/minute | 100 mg once daily |
| 30-59 mL/minute | 50 mg once daily |
| 15-29 mL/minute | Not recommended |
| Below 15 mL/minute, including renal replacement therapy | Not recommended |
For inadequate response in mild or moderate impairment, the label permits doubling the listed starting dose. Do not transfer that escalation to severe impairment.
RDM32-abrocitinib-cibinqo-1 · Source locator: 2.3, Table 1; 8.6
This is a selected renal-dose summary, not the complete atopic-dermatitis treatment protocol. Review the full JAK-inhibitor boxed warnings, infection screening and interacting medicines before treatment.
RDM32-abrocitinib-cibinqo-2 · Source locator: Boxed warning; 2; 5; 7
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=abrocitinib-cibinqo&s1=RDM32-label-abrocitinib-cibinqo&h1=fab7e33b09e92b23a8d0ed51e202464347eeee8547a6181c26cedf4b21a046fb